**1. Introduction**

### **1.1 Concept**

360 Biomarker

van Winden, A. W., van den Broek, I., Gast, M. C., Engwegen, J. Y., Sparidans, R. W., van

Walsh, P. C. (2010). Chemoprevention of Prostate Cancer. *New England Journal of Medicine,* 

Walther, T. C., & Mann, M. (2010). Mass spectrometry-based proteomics in cell biology.

Weng, W. H., Ahlen, J., Astrom, K., Lui, W. O., & Larsson, C. (2005). Prognostic impact of

Whiteaker, J. R., Lin, C., Kennedy, J., Hou, L., Trute, M., Sokal, I., et al. (2011). A targeted

Whiteaker, J. R., Zhao, L., Anderson, L., & Paulovich, A. G. (2010). An automated and

Wilm, M. (2011). Principles of electrospray ionization. *Molecular & Cellular Proteomics, 10*(7),

Wright, M. E., Eng, J., Sherman, J., Hockenbery, D. M., Nelson, P. S., Galitski, T., et al. (2004).

Wright, M. E., Han, D. K., & Aebersold, R. (2005). Mass spectrometry-based expression profiling of clinical prostate cancer. *Molecular & Cellular Proteomics, 4*(4), 545-554. Wu, W. W., Wang, G. H., Baek, S. J., & Shen, R. F. (2006). Comparative study of three

Yang, C. M., Yen, Y. T., Huang, C. S., & Hu, M. L. (2011). Growth inhibitory efficacy of

Yetley, E. A., Pfeiffer, C. M., Phinney, K. W., Fazili, Z., Lacher, D. A., Bailey, R. L., et al.

Yu, Y. P., & Luo, J. H. (2006). Myopodin-mediated suppression of prostate cancer cell migration involves interaction with zyxin. *Cancer Research, 66*(15), 7414-7419. Zeliadt, S. B., & Ramsey, S. D. (2010). Cost-effectiveness of prostate cancer chemoprevention

Zhang, H., Liu, Q., Zimmerman, L. J., Ham, A. J., Slebos, R. J., Rahman, J., et al. (2011).

Zolotarjova, N., Martosella, J., Nicol, G., Bailey, J., Boyes, B. E., & Barrett, W. C. (2005).

biomarkers. *Molecular & Cellular Proteomics, 9*(1), 184-196.

MALDI TOF/TOF. *Journal of Proteome Research, 5*(3), 651-658.

human prostate cancer cells. *Genome Biology, 5*(1).

cancer. *Journal of Proteome Research, 9*(8), 3781-3788.

*Journal of Cell Biology, 190*(4), 491-500.

*Clinical Cancer Research, 11*(17), 6198-6204.

*362*(13), 1237-1238.

*29*(7), 625-634.

M111 009407.

*Research, 58*(14), 3150-3153.

*10*(5), 505-508.

*5*(13), 3304-3313.

006593.

*Journal of Clinical Nutrition, 94*(1), 303S-312S.

Dulken, E. J., et al. (2010). Serum degradome markers for the detection of breast

immunohistochemical expression of ezrin in highly malignant soft tissue sarcomas.

proteomics-based pipeline for verification of biomarkers in plasma. *Nat Biotechnol,* 

multiplexed method for high throughput peptide immunoaffinity enrichment and multiple reaction monitoring mass spectrometry-based quantification of protein

Identification of androgen-coregulated protein networks from the microsomes of

proteomic quantitative methods, DIGE, cICAT, and iTRAQ, using 2D gel- or LC-

lycopene and beta-carotene against androgen-independent prostate tumor cells xenografted in nude mice. *Molecular Nutrition & Food Research, 55*(4), 606-612. Yang, M. H., & Sytkowski, A. J. (1998). Differential expression and androgen regulation of

the human selenium-binding protein gene hSP56 in prostate cancer cells. *Cancer* 

(2011). Biomarkers of folate status in NHANES: a roundtable summary. *American* 

among high-risk men. *Expert Review of Pharmacoeconomics & Outcomes Research,* 

Methods for peptide and protein quantitation by liquid chromatography-multiple reaction monitoring mass spectrometry. *Molecular & Cellular Proteomics, 10*(6), M110

Differences among techniques for high-abundant protein depletion. *Proteomics,* 
